- Trials with a EudraCT protocol (76)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
76 result(s) found for: Myelofibrosis (MF).
Displaying page 1 of 4.
EudraCT Number: 2011-005066-38 | Sponsor Protocol Number: CINC424AGB02 | Start Date*: 2012-03-09 |
Sponsor Name:Novartis Pharmaceuticals UK Ltd | ||
Full Title: A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelof... | ||
Medical condition: primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV MF) or Post essential thrombocythemia myelofibrosis (PET-MF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-024473-39 | Sponsor Protocol Number: CINC424A2401 | Start Date*: 2011-06-22 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofib... | ||
Medical condition: primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV MF) or Post essential thrombocythemia myelofibrosis (PET-MF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed) PT (Completed) SK (Completed) PL (Completed) IT (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004023-20 | Sponsor Protocol Number: CLDE225X2116 | Start Date*: 2013-06-21 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A. | |||||||||||||
Full Title: A Phase Ib/II, open-label, multi-center, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis | |||||||||||||
Medical condition: myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Prematurely Ended) IE (Prematurely Ended) IT (Completed) DE (Completed) NL (Prematurely Ended) FR (Prematurely Ended) DK (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003123-42 | Sponsor Protocol Number: INCB39110-213 | Start Date*: 2021-03-17 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post–Polycythemi... | |||||||||||||
Medical condition: Primary Myelofibrosis or Secondary Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) FR (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) PL (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019790-15 | Sponsor Protocol Number: APL-B-020-10 | Start Date*: 2010-09-06 | |||||||||||
Sponsor Name:PHARMA MAR | |||||||||||||
Full Title: Open-label, Phase II Clinical Trial of Aplidin (Plitidepsin) in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis | |||||||||||||
Medical condition: - primary myelofibrosis (PMF), - post-polycythemia vera myelofibrosis (post-PV MF), or - post-essential thrombocythemia myelofibrosis (post-ET MF). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004239-21 | Sponsor Protocol Number: PAC325 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:CTI BioPharma Corp. | |||||||||||||
Full Title: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemi... | |||||||||||||
Medical condition: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Completed) IT (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009858-24 | Sponsor Protocol Number: CINC424A2352 | Start Date*: 2009-05-18 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment-II | |||||||||||||
Medical condition: Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) SE (Completed) FR (Completed) DE (Completed) AT (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000097-15 | Sponsor Protocol Number: M16-191 | Start Date*: 2020-11-20 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis | |||||||||||||
Medical condition: Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Ongoing) SE (Ongoing) NL (Ongoing) AT (Ongoing) GR (Ongoing) IT (Ongoing) BG (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001462-16 | Sponsor Protocol Number: 26866138-CAN-2002, VEL-04-118 | Start Date*: 2006-03-14 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: A phase II Study of Bortezomib (Velcade), a proteasome Inhibitor, in treating patients with idiopathic Myelofibrosis (IM) randomized to receive new investigational drugs. | |||||||||||||
Medical condition: idiopathic myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001718-80 | Sponsor Protocol Number: PRM-151G-101 | Start Date*: 2016-02-18 | |||||||||||||||||||||
Sponsor Name:Promedior, Inc | |||||||||||||||||||||||
Full Title: A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) | |||||||||||||||||||||||
Medical condition: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) FR (Completed) DE (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-018965-42 | Sponsor Protocol Number: CC-4047-MF-002 | Start Date*: 2010-11-03 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE-3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE EFFICACY AND SAFETY OF POMALIDOMIDE IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM -ASSOCIATED M... | |||||||||||||
Medical condition: Myeloproliferative Neoplasm (MPN) Associated Myelofibrosis defined as primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF) and post-essential thrombocythemia myelofibrosis... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) AT (Completed) IT (Completed) ES (Completed) BE (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003809-60 | Sponsor Protocol Number: XPORT-MF-035 | Start Date*: 2021-07-27 | |||||||||||||||||||||||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||||||||||||
Full Title: A phase 2, randomized, open-label, multicenter study to evaluate safety and efficacy of single agent selinexor versus treatment of physician’s choice in patients with previously treated myelofibrosis | |||||||||||||||||||||||||||||||||
Medical condition: Myelofibrosis | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: HU (Completed) PL (Temporarily Halted) GR (Completed) IT (Ongoing) ES (Temporarily Halted) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003288-24 | Sponsor Protocol Number: GRN163LMYF3001 | Start Date*: 2021-05-10 | |||||||||||
Sponsor Name:Geron Corporation | |||||||||||||
Full Title: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/... | |||||||||||||
Medical condition: Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Trial now transitioned) DK (Trial now transitioned) FR (Ongoing) HU (Ongoing) AT (Ongoing) PT (Trial now transitioned) BG (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003130-21 | Sponsor Protocol Number: INCB50465-313 | Start Date*: 2021-03-10 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis | |||||||||||||
Medical condition: myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) FR (Ongoing) DK (Completed) FI (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004350-42 | Sponsor Protocol Number: SRA-MMB-4365/219627 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Research @ Development Limited | |||||||||||||
Full Title: Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | |||||||||||||
Medical condition: Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) DK (Ongoing) BG (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Ongoing) NL (Ongoing) BE (Ongoing) IT (Ongoing) AT (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004000-19 | Sponsor Protocol Number: PAC326 | Start Date*: 2014-05-12 | |||||||||||
Sponsor Name:CTI BioPharma Corp. | |||||||||||||
Full Title: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Ess... | |||||||||||||
Medical condition: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) GB (Completed) DE (Temporarily Halted) HU (Prematurely Ended) CZ (Prematurely Ended) NL (Temporarily Halted) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002393-27 | Sponsor Protocol Number: TL895201 | Start Date*: 2021-05-28 | ||||||||||||||||
Sponsor Name:Telios Pharma, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis... | ||||||||||||||||||
Medical condition: Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, Indolent Systemic Mastocytosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) HU (Ongoing) BE (Ongoing) BG (Ongoing) PL (Ongoing) IT (Ongoing) HR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005414-10 | Sponsor Protocol Number: MNM-study | Start Date*: 2012-02-08 | |||||||||||
Sponsor Name:The Nordic Myeloproliferative Neoplasm Group | |||||||||||||
Full Title: Nordic Study of Multiferon® in Early-Stage Primary Myelofibrosis - a Multicentre Pilot Study | |||||||||||||
Medical condition: early and fibrotic stages of primary myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003227-15 | Sponsor Protocol Number: KER050-MF-301 | Start Date*: 2022-02-08 | ||||||||||||||||||||||||||
Sponsor Name:Keros Therapeutics, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis | ||||||||||||||||||||||||||||
Medical condition: Myelfibrosis (MF) MF- associated cytopenias | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000916-27 | Sponsor Protocol Number: RG_19-030 | Start Date*: 2020-11-12 | ||||||||||||||||
Sponsor Name:University of Birmingham | ||||||||||||||||||
Full Title: Investigation into the combination of PLX2853 with ruxolitinib in patients with intermediate-2 or high risk myelofibrosis not receiving an adequate response with ruxolitinib alone. | ||||||||||||||||||
Medical condition: Myelofibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.